ArticleNature microbiology2023
Inhibiting fatty acid synthesis overcomes colistin resistance.
Article in Nature microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 72 citations in OpenAlex.
- Natural molecule potentiates colistin efficacyVirulence · 2026Article
- Disruption ofVirulence · 2026Article
- Glutamate Potentiates Meropenem Killing of Carbapenem-ResistantACS omega · 2026Article
- A genome-wide CRISPRi screen identifies homologous recombination pathway as potential target for broad-spectrum antibiotic adjuvants.Journal of advanced research · 2026Article
- Streptavidins Coordinate Biotin Sequestration and Self-Resistance Within a Biotin-Pathway Antibiotic Network.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tuspetinib enhances the activity of polymyxin B by inhibiting the GlcNAc6P deacetylase.The Journal of antibiotics · 2026Article
- The precisely regulated keystone taxa facilitate microbial mineralization of soil organic phosphorus via niche partitioning.NPJ biofilms and microbiomes · 2026Article
- Evaluation of the combined efficacy of carvone and colistin against colistin-resistantMicrobiology spectrum · 2026Article
- Discovery of HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Rule-Based Ion Prediction with Orthogonal Constraints Reveals Bacterial Phospholipid Remodeling Signatures.Antibiotics (Basel, Switzerland) · 2026Article
- Targeting MCR-3 and membrane biosynthesis: mechanistic insights into pterostilbene-colistin synergy.Microbiology spectrum · 2026Article
- Perspectives on Colistin-An Old Antibiotic with Renewed Relevance in Modern Medicine.International journal of molecular sciences · 2026Review
- Bacterial cell envelope-targeting antibiotics.Nature reviews. Microbiology · 2026Review
- FabH (β-Ketoacyl-ACP Synthase III) -- Promising Novel Antibacterial Target and Its Inhibitors.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Article
- Emergence of Polymyxin Resistance Driven by a PhoQ Mutation in KPC-2-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- A lignan compound regulates LPS modifications via PmrA/B signaling cascades to potentiate colistin efficacy in vivo.PLoS pathogens · 2025Article
- Assembly and inhibition of transferable TMexCD1-TOprJ1 efflux pump.Nature communications · 2025Article
- Membrane Proteins ClcB, PtsI, and YcaM Mediate the Bactericidal Effects of Colistin inACS infectious diseases · 2025Article
- Asymmetric volume-mediated buffer control overcomes sensitivity limits in one-pot RAA-CRISPR/Cas12a visual detection.Analytical and bioanalytical chemistry · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Treating multidrug-resistant infections has increasingly relied on last-resort antibiotics, including polymyxins, for example colistin. As polymyxins are given routinely, the prevalence of their resistance is on the rise and increases mortality rates of sepsis patients. The global dissemination of plasmid-borne colistin resistance, driven by the emergence of mcr-1, threatens to diminish the therapeutic utility of polymyxins from an already shrinking antibiotic arsenal. Restoring sensitivity to polymyxins using combination therapy with sensitizing drugs is a promising approach to reviving its clinical utility. Here we describe the ability of the biotin biosynthesis inhibitor, MAC13772, to synergize with colistin exclusively against colistin-resistant bacteria. MAC13772 indirectly disrupts fatty acid synthesis (FAS) and restores sensitivity to the last-resort antibiotic, colistin. Accordingly, we found that combinations of colistin and other FAS inhibitors, cerulenin, triclosan and Debio1452-NH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.